دوا کے تعاملات
Nivolumab + Ponesimod
شدت: معتدل
Nivolumab and Ponesimod: moderate interaction.
آخری تازہ کاری
صرف صحت کے پیشہ ور افراد کے لیے — محض حوالے کے طور پر۔ یہ صفحہ مختصر خلاصہ ہے، طبی مشورہ نہیں، اور سرکاری لیبل یا طبی فیصلے کا متبادل نہیں۔ تجویز یا فراہمی سے پہلے ہمیشہ تصدیق کریں۔
اس صفحے کا طبی مواد صرف انگریزی میں دستیاب ہے۔
خلاصہ
Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
اس تعامل کا آسان لفظوں میں مطلب
Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nivolumab belongs to Oncology; Ponesimod belongs to Central Nervous System.
ایسا کیوں ہوتا ہے
Ponesimod sequesters lymphocytes in lymphoid tissue via S1P receptor modulation, which may counteract the T-cell activation sought with PD-1 blockade.
کیا کرنا ہے
Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
فارماسسٹ سے کیا پوچھیں
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ اراکین کے لیے
پورا صفحہ کھولیں
Nivolumab اور Ponesimod کے لیے مکمل طبی انتظام کی رہنمائی، اضافی نوٹس، شواہد کی تفصیل اور پورے نسخے کا تعامل چیکر کھولنے کے لیے اکاؤنٹ بنائیں اور Pro+ ٹرائل شروع کریں۔
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
ویب پر 7 دن تک Pro+ مفت آزمائیں۔ کارڈ کی ضرورت نہیں۔
Nivolumab کے دیگر تعاملات
Ponesimod کے دیگر تعاملات
- Fingolimod + Ponesimod مانع استعمال
- Ponesimod + Siponimod مانع استعمال
- Amiodarone + Ponesimod شدید
- Amisulpride + Ponesimod شدید
- Anagrelide + Ponesimod شدید
- Anti-thymocyte + Ponesimod شدید
اکثر پوچھے جانے والے سوالات
Can I take Nivolumab with Ponesimod?
MediHelp rates the interaction as moderate. Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
How serious is the interaction between Nivolumab and Ponesimod?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
MediHelp ایپ میں مکمل مونوگراف، خوراک اور تعامل چیکر
MediHelp ایپ میں مکمل حوالہ کھولیں، متعدد ادویات کے تعاملات جانچیں اور خوراک کے ٹولز استعمال کریں۔
